hydrochlorothiazide has been researched along with Kidney Failure, Chronic in 41 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)." | 9.11 | A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 9.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals." | 5.16 | Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)." | 5.11 | A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 5.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "Eleven patients with hypertension secondary to renal disease were treated with hydrochlorothiazide or furosemide plus other drugs to normalize blood pressure." | 3.66 | Use of diuretics in treatment of hypertension secondary to renal disease. ( Bank, N; Lief, PD; Piczon, O, 1978) |
| " The dose-response curves for HCTZ and FU were both relatively flat: doubling the dose of each produced statistically insignificant increases in sodium excretion." | 2.68 | Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. ( Knauf, H; Mutschler, E, 1995) |
| "Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the active converting enzyme inhibitor enalaprilat." | 2.37 | An overview of the clinical pharmacology of enalapril. ( Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF, 1984) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "In the present study we induced chronic renal failure by administration of lithium for 16 weeks to new-born rats, and examined the spontaneous course of this nephropathy and the effects of antihypertensive treatment with either perindopril (12 mg/kg diet) or hydrochlorothiazide (500-1000 mg/kg diet) during a 24 weeks follow up period without lithium." | 1.30 | Effects of perindopril and hydrochlorothiazide on the long-term progression of lithium-induced chronic renal failure in rats. ( Christensen, S; Hansen, AK; Marcussen, N; Shalmi, M, 1997) |
| "Enalapril treatment significantly reduced proteinuria (731 +/- 23 vs." | 1.29 | Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| " The effects of increases of calcitriol dosage and modifications of calciuria with hydrochlorothiazide were systematically examined." | 1.27 | Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. ( Chan, JC; Santos, F; Smith, MJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (51.22) | 18.7374 |
| 1990's | 7 (17.07) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Handler, J | 1 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 1 |
| Bakris, GL | 3 |
| Sarafidis, PA | 1 |
| Weir, MR | 2 |
| Dahlöf, B | 2 |
| Pitt, B | 2 |
| Jamerson, K | 1 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 2 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 2 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Lerma, EV | 1 |
| Ishimitsu, T | 1 |
| Ohno, E | 1 |
| Nakano, N | 1 |
| Furukata, S | 1 |
| Akashiba, A | 1 |
| Minami, J | 1 |
| Numabe, A | 1 |
| Matsuoka, H | 1 |
| Devereux, RB | 1 |
| Kjeldsen, SE | 1 |
| Wright, JT | 1 |
| Hua, TA | 1 |
| Hester, RA | 1 |
| Velazquez, E | 1 |
| Jamerson, KA | 1 |
| SACKNER, MA | 1 |
| WALLACK, AA | 1 |
| BELLET, S | 1 |
| Ogata, S | 1 |
| Sharyo, S | 1 |
| Hinman, DJ | 1 |
| Manabe, S | 1 |
| Toto, RD | 1 |
| McCullough, PA | 1 |
| Dussol, B | 1 |
| Moussi-Frances, J | 1 |
| Morange, S | 1 |
| Somma-Delpero, C | 1 |
| Mundler, O | 1 |
| Berland, Y | 1 |
| Lebel, M | 1 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Larivière, R | 1 |
| Davies, RO | 1 |
| Gomez, HJ | 1 |
| Irvin, JD | 1 |
| Walker, JF | 1 |
| Wollam, GL | 1 |
| Tarazi, RC | 1 |
| Bravo, EL | 1 |
| Dustan, HP | 1 |
| Madkour, H | 1 |
| Gadallah, M | 1 |
| Riveline, B | 1 |
| Plante, GE | 1 |
| Massry, SG | 1 |
| Fliser, D | 1 |
| Schröter, M | 1 |
| Neubeck, M | 1 |
| Ritz, E | 2 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Knauf, H | 1 |
| Mutschler, E | 1 |
| Frohlich, ED | 1 |
| Christensen, S | 1 |
| Shalmi, M | 1 |
| Hansen, AK | 1 |
| Marcussen, N | 1 |
| Schwenger, V | 1 |
| Zeier, M | 1 |
| Ruggenenti, P | 1 |
| Brenner, BM | 1 |
| Remuzzi, G | 1 |
| Bald, M | 1 |
| Vester, U | 1 |
| Wingen, AM | 1 |
| Bennett, WM | 1 |
| McDonald, WJ | 1 |
| Kuehnel, E | 1 |
| Hartnett, MN | 1 |
| Porter, GA | 1 |
| Bank, N | 1 |
| Lief, PD | 1 |
| Piczon, O | 1 |
| Nakahama, H | 1 |
| Orita, Y | 1 |
| Yamazaki, M | 1 |
| Itoh, S | 1 |
| Okuda, T | 1 |
| Yamaji, A | 1 |
| Miwa, Y | 1 |
| Yanase, M | 1 |
| Fukuhara, Y | 1 |
| Kamada, T | 1 |
| Zahid, M | 1 |
| Krumlovsky, FA | 1 |
| Roxe, D | 1 |
| del Greco, F | 1 |
| Mistovich, M | 1 |
| Santos, F | 1 |
| Smith, MJ | 1 |
| Chan, JC | 1 |
| Seybold, G | 1 |
| Niemeyer, G | 1 |
| Tschöpa, J | 1 |
| Fukuchi, S | 1 |
| Nakajima, K | 1 |
| Takenouchi, T | 1 |
| Nishisato, K | 1 |
| Siegler, RL | 1 |
| Limas, CJ | 1 |
| Freis, ED | 2 |
| Fishback, DB | 1 |
| Paris, GL | 1 |
| Macoul, KL | 1 |
| Muiesan, G | 1 |
| Motolese, M | 1 |
| Petz, E | 1 |
| Todisco, T | 1 |
| Szende, L | 1 |
| Radó, JP | 1 |
| Takó, J | 1 |
| Dévényi, I | 1 |
| Cagli, V | 1 |
| Ruotolo, V | 1 |
| Bossini, A | 1 |
| Bologna, E | 1 |
| Bartoli, E | 2 |
| Molaschi, M | 2 |
| Viara, A | 2 |
| Milanese, U | 2 |
| Matone, S | 2 |
| Ackerman, GL | 1 |
| Flanigan, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
2 reviews available for hydrochlorothiazide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2011 |
An overview of the clinical pharmacology of enalapril.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Di | 1984 |
11 trials available for hydrochlorothiazide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2012 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.
Topics: Adult; Aged; Chlorides; Cross-Over Studies; Diuretics; Double-Blind Method; Furosemide; Humans; Hydr | 2005 |
Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia.
Topics: Adult; Body Weight; Clinical Trials as Topic; Diuretics; Drug Combinations; Female; Furosemide; Huma | 1982 |
Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension.
Topics: Body Weight; Creatinine; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertensi | 1995 |
Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure.
Topics: Adult; Aged; Cross-Over Studies; Diuresis; Diuretics; Drug Therapy, Combination; Female; Humans; Hyd | 1994 |
Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure.
Topics: Adult; Aged; Calcium; Chlorides; Diuretics; Dose-Response Relationship, Drug; Drug Synergism; Electr | 1995 |
Do diuretics have antihypertensive properties independent of natriuresis?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Me | 1977 |
The combination of guanethidine and hydrochlorothiazide in the treatment of arterial hypertension with and without renal failure.
Topics: Adult; Analysis of Variance; Blood Pressure; Clinical Trials as Topic; Creatine; Drug Synergism; Fem | 1968 |
28 other studies available for hydrochlorothiazide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Lithium and antihypertensive medication: a potentially dangerous interaction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antimanic Agents; Bipolar Disorde | 2009 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
The diuretic effects of hydrochlorothiazide in congestive heart failure, cirrhosis, chronic renal disease and hypertension: preliminary report based on a study of 28 cases.
Topics: Acetazolamide; Diuretics; Edema; Heart Failure; Hydrochlorothiazide; Hypertension; Kidney Failure, C | 1959 |
Renal effects of 26-week administration of olmesartan medoxomil/hydrochlorothiazide in rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blo | 2004 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats.
Topics: Animals; Antihypertensive Agents; Cholesterol; Drug Therapy, Combination; Enalapril; Hydralazine; Hy | 1993 |
Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Diuretics; Endothe | 1997 |
Effects of perindopril and hydrochlorothiazide on the long-term progression of lithium-induced chronic renal failure in rats.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Creatinine; Disease | 1997 |
Antihypertensive therapy in renal patients - benefits and difficulties.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion.
Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diure | 2001 |
Dent's disease.
Topics: Calcium; Diuretics; Humans; Hydrochlorothiazide; Hypokalemia; Kidney Diseases; Kidney Failure, Chron | 2002 |
Use of diuretics in treatment of hypertension secondary to renal disease.
Topics: Adult; Aldosterone; Antihypertensive Agents; Creatinine; Female; Furosemide; Humans; Hydrochlorothia | 1978 |
Potentiation of furosemide by hydrochlorothiazide in chronic renal failure patients.
Topics: Adult; Aged; Drug Synergism; Female; Furosemide; Humans; Hydrochlorothiazide; Kidney Failure, Chroni | 1988 |
Central nervous system and cardiac manifestations of hydrochlorothiazide overdosage; treatment with hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Central Nervous System; Heart; Humans; Hydrochlorothiazide; Kidney Failu | 1988 |
Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.
Topics: Adolescent; Animals; Calcitriol; Calcium; Child, Preschool; Chronic Kidney Disease-Mineral and Bone | 1986 |
[The immunologically measurable excretion of insulin in the urine of non-diabetic experimental persons following the administration of a saluretic and in reduced renal function].
Topics: Antibodies; Humans; Hydrochlorothiazide; Insulin; Iodine Radioisotopes; Kidney Failure, Chronic; Kid | 1973 |
Plasma aldosterone in essential hypertension with low renin activity.
Topics: Aldosterone; Body Weight; Corticosterone; Cushing Syndrome; Furosemide; Humans; Hydrochlorothiazide; | 1974 |
Malignant hypertension in children; a patient treated with bilateral nephrectomy.
Topics: Blood Pressure; Child; Creatinine; Female; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; H | 1974 |
Minoxidil in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Evaluation Studies as Topic; Female; Follow-Up Studi | 1973 |
Fluorescein circulation time and the treatment of hypertension in the aged.
Topics: Adult; Age Factors; Aged; Blood Circulation Time; Blood Pressure; Carbamates; Ethacrynic Acid; Femal | 1973 |
Hypertension: challenge in preventive medicine.
Topics: Aged; Aneurysm; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therap | 1973 |
Reversible bullous retinal detachment in chronic renal disease.
Topics: Adult; Angiography; Diet; Female; Fluorescence; Humans; Hydrochlorothiazide; Hypertension, Renal; Hy | 1969 |
Hyperkalemia and coma associated with renal tubular acidosis in an old patient with refractory edema due to the nephrotic syndrome: furosemide-bicarbonate therapy.
Topics: Acidosis, Renal Tubular; Adrenal Cortex Hormones; Aged; Aldosterone; Bicarbonates; Coma; Edema; Furo | 1972 |
[Renal excretion of uric acid in various conditions inducing hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension, Renal; Kidney Fail | 1970 |
[Physiopathology of dilution of urine in chronic renal insufficiency following glomerulonephritis studied with administration of dihydrochlorothiazide and furosemide].
Topics: Furosemide; Glomerulonephritis; Humans; Hydrochlorothiazide; Kidney; Kidney Concentrating Ability; K | 1968 |
[Physiopathology of the renal concentration process in chronic renal insufficiency following glomerulonephritis studied with administration of dihydrochlorothiazide and furosemide].
Topics: Furosemide; Glomerulonephritis; Humans; Hydrochlorothiazide; Kidney; Kidney Concentrating Ability; K | 1968 |
Reversible insufficiency in chronic renal disease.
Topics: Aged; Blood Urea Nitrogen; Creatine; Diet Therapy; Humans; Hydrochlorothiazide; Kidney Failure, Chro | 1966 |